Z Chen1, W Deng1, Q Gong2, C Huang1, L Jiang1, M Li1, Z He1, Q Wang1, X Ma1, Y Wang1, S E Chua3, G M McAlonan3, P C Sham3, D A Collier4, P McGuire5, T Li1. 1. The Mental Health Center and Psychiatric Laboratory, West China Hospital,Sichuan University,Chengdu, Sichuan,China. 2. Huaxi MR Research Center, Department of Radiology,West China Hospital, Sichuan University,Chengdu,China. 3. Department of Psychiatry,The University of Hong Kong,Pokfulam,S.A.R. China. 4. MRC SGDP Centre, Institute of Psychiatry,King's College London,UK. 5. Division of Psychological Medicine and Psychiatry, Section of Neuroimaging,Institute of Psychiatry, King's College London,UK.
Abstract
BACKGROUND: Alterations in gray matter (GM) are commonly observed in schizophrenia. Accumulating studies suggest that the brain changes associated with schizophrenia are distributed rather than focal, involving interconnected networks of areas as opposed to single regions. In the current study we aimed to explore GM volume (GMV) changes in a relatively large sample of treatment-naive first-episode schizophrenia (FES) patients using optimized voxel-based morphometry (VBM) and covariation analysis. METHOD: High-resolution T1-weighted images were obtained using 3.0-T magnetic resonance imaging (MRI) from 86 first-episode drug-naive patients with schizophrenia and 86 age- and gender-matched healthy volunteers. Symptom severity was evaluated using the Positive and Negative Syndrome Scale (PANSS). GMV was assessed using optimized VBM and in 16 regions of interest (ROIs), selected on the basis of a previous meta-analysis. The relationships between GMVs in the ROIs were examined using an analysis of covariance (ANCOVA). RESULTS: The VBM analysis revealed that first-episode patients showed reduced GMV in the hippocampus bilaterally. The ROI analysis identified reductions in GMV in the left inferior frontal gyrus, bilateral hippocampus and right thalamus. The ANCOVA revealed different patterns of regional GMV correlations in patients and controls, including of inter- and intra-insula, inter-amygdala and insula-postcentral gyrus connections. CONCLUSIONS: Schizophrenia involves regional reductions in GMV and changes in GMV covariance in the insula, amygdala and postcentral gyrus. These findings were evident at the onset of the disorder, before treatment, and therefore cannot be attributable to the effects of chronic illness progression or medication.
BACKGROUND: Alterations in gray matter (GM) are commonly observed in schizophrenia. Accumulating studies suggest that the brain changes associated with schizophrenia are distributed rather than focal, involving interconnected networks of areas as opposed to single regions. In the current study we aimed to explore GM volume (GMV) changes in a relatively large sample of treatment-naive first-episode schizophrenia (FES) patients using optimized voxel-based morphometry (VBM) and covariation analysis. METHOD: High-resolution T1-weighted images were obtained using 3.0-T magnetic resonance imaging (MRI) from 86 first-episode drug-naive patients with schizophrenia and 86 age- and gender-matched healthy volunteers. Symptom severity was evaluated using the Positive and Negative Syndrome Scale (PANSS). GMV was assessed using optimized VBM and in 16 regions of interest (ROIs), selected on the basis of a previous meta-analysis. The relationships between GMVs in the ROIs were examined using an analysis of covariance (ANCOVA). RESULTS: The VBM analysis revealed that first-episode patients showed reduced GMV in the hippocampus bilaterally. The ROI analysis identified reductions in GMV in the left inferior frontal gyrus, bilateral hippocampus and right thalamus. The ANCOVA revealed different patterns of regional GMV correlations in patients and controls, including of inter- and intra-insula, inter-amygdala and insula-postcentral gyrus connections. CONCLUSIONS:Schizophrenia involves regional reductions in GMV and changes in GMV covariance in the insula, amygdala and postcentral gyrus. These findings were evident at the onset of the disorder, before treatment, and therefore cannot be attributable to the effects of chronic illness progression or medication.
Authors: Eric Plitman; Shinichiro Nakajima; Camilo de la Fuente-Sandoval; Philip Gerretsen; M Mallar Chakravarty; Jane Kobylianskii; Jun Ku Chung; Fernando Caravaggio; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero Journal: Eur Neuropsychopharmacol Date: 2014-08-01 Impact factor: 4.600
Authors: Boris A Gutman; Theo G M van Erp; Kathryn Alpert; Christopher R K Ching; Dmitry Isaev; Anjani Ragothaman; Neda Jahanshad; Arvin Saremi; Artemis Zavaliangos-Petropulu; David C Glahn; Li Shen; Shan Cong; Dag Alnaes; Ole Andreas Andreassen; Nhat Trung Doan; Lars T Westlye; Peter Kochunov; Theodore D Satterthwaite; Daniel H Wolf; Alexander J Huang; Charles Kessler; Andrea Weideman; Dana Nguyen; Bryon A Mueller; Lawrence Faziola; Steven G Potkin; Adrian Preda; Daniel H Mathalon; Juan Bustillo; Vince Calhoun; Judith M Ford; Esther Walton; Stefan Ehrlich; Giuseppe Ducci; Nerisa Banaj; Fabrizio Piras; Federica Piras; Gianfranco Spalletta; Erick J Canales-Rodríguez; Paola Fuentes-Claramonte; Edith Pomarol-Clotet; Joaquim Radua; Raymond Salvador; Salvador Sarró; Erin W Dickie; Aristotle Voineskos; Diana Tordesillas-Gutiérrez; Benedicto Crespo-Facorro; Esther Setién-Suero; Jacqueline Mayoral van Son; Stefan Borgwardt; Fabienne Schönborn-Harrisberger; Derek Morris; Gary Donohoe; Laurena Holleran; Dara Cannon; Colm McDonald; Aiden Corvin; Michael Gill; Geraldo Busatto Filho; Pedro G P Rosa; Mauricio H Serpa; Marcus V Zanetti; Irina Lebedeva; Vasily Kaleda; Alexander Tomyshev; Tim Crow; Anthony James; Simon Cervenka; Carl M Sellgren; Helena Fatouros-Bergman; Ingrid Agartz; Fleur Howells; Dan J Stein; Henk Temmingh; Anne Uhlmann; Greig I de Zubicaray; Katie L McMahon; Margie Wright; Derin Cobia; John G Csernansky; Paul M Thompson; Jessica A Turner; Lei Wang Journal: Hum Brain Mapp Date: 2021-09-08 Impact factor: 5.399
Authors: Sucharita S Somkuwar; Miranda C Staples; Melissa H Galinato; McKenzie J Fannon; Chitra D Mandyam Journal: Front Pharmacol Date: 2014-12-19 Impact factor: 5.810
Authors: A Batalla; N Bargalló; P Gassó; O Molina; D Pareto; S Mas; J M Roca; M Bernardo; A Lafuente; E Parellada Journal: Transl Psychiatry Date: 2015-08-25 Impact factor: 6.222